This article was originally published in The Tan Sheet
Meeting slated for Oct. 18-19 has been canceled. No agenda has been set for the next scheduled meeting dates of Dec. 2-3. Most recently, NDAC met jointly with the Arthritis Advisory Committee July 20 to consider the Rx-to-OTC switch of Merck's Flexeril 5 mg (1"The Tan Sheet" July 26, pp. 3-9)
You may also be interested in...
The ability of patients to accurately detect when they would need to use Flexeril 5 mg (cyclobenzaprine) is a significant hurdle the drug would need to overcome in a switch from the Rx to the OTC environment, according to discussions by FDA's Nonprescription Drugs and Arthritis Advisory Committees July 20.
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands